Chemomab Therapeutics CMMB
NASDAQ CMMB
$1.43 +0.13 (+10.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Chemomab Therapeutics (CMMB) Gains from Sales and Divestitures (2020)

Updated

Chemomab Therapeutics (CMMB) recorded Gains from Sales and Divestitures of $17,000 in Q4 2020.

Analysis

Chemomab Therapeutics (CMMB) Gains from Sales and Divestitures (2020) Analysis & Trends

For FY2020, Chemomab Therapeutics reported Gains from Sales and Divestitures of $36,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Chemomab Therapeutics 10.28 Mn 10.28 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 17,000.00
API Access

Chemomab Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CMMB&period=max&api_key=YOUR_API_KEY